Cited 1 times in
Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 금지영 | - |
dc.contributor.author | 박승우 | - |
dc.contributor.author | 박정엽 | - |
dc.contributor.author | 방승민 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 이희승 | - |
dc.contributor.author | 정문재 | - |
dc.contributor.author | 조중현 | - |
dc.date.accessioned | 2022-05-09T16:54:56Z | - |
dc.date.available | 2022-05-09T16:54:56Z | - |
dc.date.issued | 2022-02 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188279 | - |
dc.description.abstract | FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, and 5-fluorouracil) is a first-line chemotherapy for metastatic pancreatic cancer (PC). Chemotherapy-induced neutropenia is one of the most serious adverse events associated with advanced PC. Although UGT1A1 polymorphisms are associated with the metabolism of irinotecan, their role as surrogate markers for FOLFIRINOX-induced neutropenia has not been confirmed. We investigated risk factors for FN-in particular, UGT1A1 polymorphisms-in PC patients receiving FOLFIRINOX, using a single-center cohort registry. To investigate the association between UGT1A1 polymorphisms and FN, we divided patients into three groups based on the predicted UGT1A1 phenotype: extensive metabolizer (EM) vs. intermediate metabolizer (IM) vs. poor metabolizer (PM). A total of 154 patients (FN group (n = 31) vs. non-FN group (n = 123)) receiving first-line FOLFIRINOX were identified between December 2017 and July 2020. The Cox regression analysis showed that female sex (HR: 2.20; p = 0.031), Eastern Cooperative Oncology Group performance status = 1 (HR: 2.83; p = 0.008), UGT1A1 IM (HR: 4.30; p = 0.004), and UGT1A1 PM (HR: 4.03; p = 0.028) were statistically significant risk factors for FN. We propose that UGT1A1 is the strongest predictive factor for FN and that this gene should be screened prior to the administration of chemotherapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jiyoung Keum | - |
dc.contributor.googleauthor | Hee Seung Lee | - |
dc.contributor.googleauthor | Jung Hyun Jo | - |
dc.contributor.googleauthor | Moon Jae Chung | - |
dc.contributor.googleauthor | Jeong Youp Park | - |
dc.contributor.googleauthor | Seung Woo Park | - |
dc.contributor.googleauthor | Si Young Song | - |
dc.contributor.googleauthor | Seungmin Bang | - |
dc.identifier.doi | 10.3390/cancers14051244 | - |
dc.contributor.localId | A05992 | - |
dc.contributor.localId | A01551 | - |
dc.contributor.localId | A01647 | - |
dc.contributor.localId | A01786 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A03349 | - |
dc.contributor.localId | A03602 | - |
dc.contributor.localId | A03912 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 35267552 | - |
dc.subject.keyword | FOLFIRINOX | - |
dc.subject.keyword | UGT1A1 | - |
dc.subject.keyword | febrile neutropenia | - |
dc.subject.keyword | neutropenia | - |
dc.subject.keyword | pancreatic cancer | - |
dc.contributor.alternativeName | Keum, Jiyoung | - |
dc.contributor.affiliatedAuthor | 금지영 | - |
dc.contributor.affiliatedAuthor | 박승우 | - |
dc.contributor.affiliatedAuthor | 박정엽 | - |
dc.contributor.affiliatedAuthor | 방승민 | - |
dc.contributor.affiliatedAuthor | 송시영 | - |
dc.contributor.affiliatedAuthor | 이희승 | - |
dc.contributor.affiliatedAuthor | 정문재 | - |
dc.contributor.affiliatedAuthor | 조중현 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1244 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.14(5) : 1244, 2022-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.